|
Name |
Crinamidine
|
| Molecular Formula | C17H19NO5 | |
| IUPAC Name* |
(1S,13R,15R,16S,18R)-9-methoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.01,13.02,10.04,8.016,18]icosa-2,4(8),9-trien-15-ol
|
|
| SMILES |
COC1=C2CN3CC[C@@]4([C@H]3C[C@H]([C@H]5[C@@H]4O5)O)C2=CC6=C1OCO6
|
|
| InChI |
InChI=1S/C17H19NO5/c1-20-13-8-6-18-3-2-17(9(8)4-11-15(13)22-7-21-11)12(18)5-10(19)14-16(17)23-14/h4,10,12,14,16,19H,2-3,5-7H2,1H3/t10-,12-,14+,16+,17+/m1/s1
|
|
| InChIKey |
HHEOZJCKMANJQV-CUQLUGJVSA-N
|
|
| Synonyms |
crinamidine; NSC709877; NSC-709877; C12168; CHEBI:31436; Q27114310; (1S,13R,15R,16S,18R)-9-methoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.01,13.02,10.04,8.016,18]icosa-2,4(8),9-trien-15-ol; 6793-66-4
|
|
| CAS | NA | |
| PubChem CID | 399204 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 317.34 | ALogp: | 0.8 |
| HBD: | 1 | HBA: | 6 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 63.7 | Aromatic Rings: | 6 |
| Heavy Atoms: | 23 | QED Weighted: | 0.785 |
| Caco-2 Permeability: | -5.353 | MDCK Permeability: | 0.00002340 |
| Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.965 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.007 |
| 30% Bioavailability (F30%): | 0.523 |
| Blood-Brain-Barrier Penetration (BBB): | 0.992 | Plasma Protein Binding (PPB): | 22.47% |
| Volume Distribution (VD): | 2.275 | Fu: | 63.31% |
| CYP1A2-inhibitor: | 0.173 | CYP1A2-substrate: | 0.879 |
| CYP2C19-inhibitor: | 0.086 | CYP2C19-substrate: | 0.848 |
| CYP2C9-inhibitor: | 0.017 | CYP2C9-substrate: | 0.617 |
| CYP2D6-inhibitor: | 0.758 | CYP2D6-substrate: | 0.697 |
| CYP3A4-inhibitor: | 0.677 | CYP3A4-substrate: | 0.702 |
| Clearance (CL): | 13.086 | Half-life (T1/2): | 0.608 |
| hERG Blockers: | 0.227 | Human Hepatotoxicity (H-HT): | 0.748 |
| Drug-inuced Liver Injury (DILI): | 0.054 | AMES Toxicity: | 0.113 |
| Rat Oral Acute Toxicity: | 0.73 | Maximum Recommended Daily Dose: | 0.891 |
| Skin Sensitization: | 0.087 | Carcinogencity: | 0.778 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
| Respiratory Toxicity: | 0.941 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001089 | ![]() |
0.617 | D0T6RC | ![]() |
0.300 | ||
| ENC002961 | ![]() |
0.307 | D04TDQ | ![]() |
0.277 | ||
| ENC000702 | ![]() |
0.293 | D03DIG | ![]() |
0.262 | ||
| ENC003230 | ![]() |
0.283 | D0X5KF | ![]() |
0.250 | ||
| ENC000361 | ![]() |
0.246 | D0D4HN | ![]() |
0.246 | ||
| ENC002626 | ![]() |
0.245 | D0L1JW | ![]() |
0.246 | ||
| ENC003767 | ![]() |
0.224 | D0R9VR | ![]() |
0.245 | ||
| ENC004130 | ![]() |
0.222 | D03SKD | ![]() |
0.234 | ||
| ENC000812 | ![]() |
0.216 | D04JHN | ![]() |
0.233 | ||
| ENC002159 | ![]() |
0.216 | D0WE3O | ![]() |
0.233 | ||